Diabetologia

, Volume 57, Issue 5, pp 1084–1085

Should women with diabetic nephropathy considering pregnancy continue ACE inhibitor or angiotensin II receptor blocker therapy until pregnancy is confirmed? Reply to Lewis G and Maxwell AP [letter]

  • Peter W. G. Tennant
  • Svetlana V. Glinianaia
  • Rudy W. Bilous
  • Judith Rankin
  • Ruth Bell
Letter

Keywords

ACE inhibitors Angiotensin II receptor antagonists HbA1c Hypertension Nephropathy Pregnancy 

Abbreviations

ACEI

ACE inhibitor

ARB

Angiotensin II receptor blocker

References

  1. 1.
    Lewis G, Maxwell AP (2014) Should women with diabetic nephropathy considering pregnancy continue ACE inhibitor or angiotensin II receptor blocker therapy until pregnancy is confirmed? Diabetologia doi:10.1007/s00125-014-3188-x
  2. 2.
    Bell R, Glinianaia SV, Tennant PWG, Bilous RW, Rankin J (2012) Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study. Diabetologia 55:936–947CrossRefGoogle Scholar
  3. 3.
    Tennant PWG, Glinianaia SV, Bilous RW, Rankin J, Bell R (2014) Pre-existing diabetes, maternal haemoglobin, and the risks of fetal and infant death: a population-based study. Diabetologia 57:285–294CrossRefPubMedGoogle Scholar
  4. 4.
    Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD (2012) Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 60:444–450CrossRefPubMedGoogle Scholar
  5. 5.
    Cooper WO, Hernandez-Diaz S, Arbogast PG et al (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:2443–2451CrossRefPubMedGoogle Scholar
  6. 6.
    Li D-K, Yang C, Andrade S, Tavares V, Ferber J (2011) Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 343:d5931PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Walfisch A, Al-maawali A, Moretti ME et al (2011) Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 31:465–472CrossRefPubMedGoogle Scholar
  8. 8.
    Tennant PWG, Newham JJ, Bell R, Rankin J (2011) Studies of congenital anomalies should capture all cases, not just live births. BMJ (electronic letter). Available from www.bmj.com/rapid-response/2011/11/03/studies-congenital-anomalies-should-capture-all-cases-not-just-live-births. Accessed 4 February 2014

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Peter W. G. Tennant
    • 1
  • Svetlana V. Glinianaia
    • 1
  • Rudy W. Bilous
    • 2
    • 3
  • Judith Rankin
    • 1
    • 4
  • Ruth Bell
    • 1
    • 4
  1. 1.Institute of Health & SocietyNewcastle UniversityNewcastle upon TyneUK
  2. 2.Institute of Cellular MedicineNewcastle UniversityNewcastle upon TyneUK
  3. 3.James Cook University HospitalSouth Tees NHS TrustMiddlesbroughUK
  4. 4.Regional Maternity Survey OfficePublic Health EnglandNewcastle upon TyneUK

Personalised recommendations